Project Grant R01EB037656
Award Date 8/15/26
Completion Date 6/30/30
Dollars Obligated $548K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Drexel University $584,755 for a Project Grant (R01AI192491) on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds the engineering of biomaterial-based dendritic cell therapies for antigen-specific immune tolerance. The project develops sustained-release microparticles incorporating an immunomodulatory combination (PPI9: CEP-33779 and R848) to generate long-lived, potent...
- The National Institute of Allergy and Infectious Diseases awarded Drexel University $222,786 on June 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop injectable acellular hydrogels for local immunoregulation and tolerance in autoimmune diseases. The research addresses the imbalance of pro-inflammatory and autoreactive T cells against regulatory T cells (Tregs) that underlies autoimmune disease onset and progression. Existing systemic immunosuppression...
- The National Institute of Allergy and Infectious Diseases awarded $452,835 to the University of Pittsburgh on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate novel nanobiologic approaches for reversing graft rejection in transplant recipients. The research targets innate immune memory responses that drive persistent T-cell–mediated rejection despite standard immunosuppressive treatment. The project investigates the role of heat shock...
- The National Institute of Biomedical Imaging and Bioengineering awarded The Johns Hopkins University $598,859 on June 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop antigen-presentation modulating nanoparticles for improved immunization. The recipient is developing a platform technology based on biodegradable poly(beta-amino ester) nanoparticles capable of delivering nucleic acid cargo to antigen-presenting...
- Federal Grant Award Summary Drexel University received a $152,250 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 16, 2025, with completion targeted for June 30, 2027. The research project, titled "Placating Death Eaters: Tuning Macrophage Metabolism and Phenotype via Nanoparticles," develops cyclodextrin nanoparticles (CDNPs) as a delivery mechanism to modulate...
- The National Institute of Allergy and Infectious Diseases awarded Drexel University $624,806 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and characterize nanotrap therapeutic vaccines for HIV treatment. The project, titled "Nanotrap Therapeutic Vaccines for HIV Virion Capture and Infected Cell Targeting" (R01AI203404), will engineer liposomal nanoparticles displaying multivalent CD4 mimetic ligands designed to capture...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, College Park $722,262 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on guiding innate signaling in skin with microneedle arrays to promote durable antigen-specific tolerance during autoimmunity. The project runs through January 31, 2031, with work performed at College Park, Maryland. The research addresses autoimmune diseases including...
- The National Institute of Biomedical Imaging and Bioengineering awarded $645,265 to The Trustees of The University of Pennsylvania on June 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop DNA-loaded lipid nanoparticles (DNA-LNPs) for treating chronic diseases including atherosclerosis and emphysema. The research addresses toxicity barriers that have prevented DNA-LNP development for two decades. Prior...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $148,614 to Massachusetts Institute of Technology on January 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop glycopolymers designed to enhance interactions between immune cells and pathogenic bacteria, creating "cellular glues" that leverage the body's innate immune mechanisms as an alternative to...
- The National Institute of Biomedical Imaging and Bioengineering awarded $182,558 to Iowa State University of Science and Technology on May 6, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a bioinspired drug discovery strategy for personalized combination immunoregulatory therapeutics. The research leverages the foreign body response within subcutaneous biomaterial scaffold implants to identify...